---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-285572"
form_type: "8-K/A"
ticker: "QNCX"
cik: "0001662774"
company_name: "Quince Therapeutics, Inc."
filed_at: "2026-06-26T20:31:01+00:00"
generated_at: "2026-06-26T20:32:43.011970+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Quince Therapeutics announces 1-for-20 reverse stock split effective June 29, 2026

## Summary
- Reverse stock split ratio set at 1-for-20, approved by board after stockholder authorization.
- Certificate of Amendment filed with Delaware; effective 11:59 pm ET June 29.
- Shares trade split-adjusted on Nasdaq starting June 30; new CUSIP 22053A305.
- Outstanding shares reduce from ~19.56M to ~0.98M; fractional shares rounded up.
- All options and warrants proportionally adjusted; Equiniti Trust acts as exchange agent.

## SEC filing metadata
- accession: 0001193125-26-285572
- form_type: 8-K/A
- ticker: QNCX
- cik: 0001662774
- company_name: Quince Therapeutics, Inc.
- filed_at: 2026-06-26T20:31:01+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 3.03
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1662774/000119312526285572/0001193125-26-285572-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1662774/000119312526285572/d30985d8ka.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-285572
- JSON: https://secwatch.observer/filing/0001193125-26-285572.json
- Plain text: https://secwatch.observer/filing/0001193125-26-285572.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.